Trastuzumab plus Pertuzumab

DRUG2 trials

Sponsors

University of Maryland, Baltimore, Canadian Cancer Trials Group

Conditions

Advanced Solid TumorsLymphoma, Non-HodgkinMetastatic Breast CancerMultiple Myeloma

Phase 2

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

TerminatedNCT02000596

University of Maryland, BaltimoreMetastatic Breast Cancer

Start: 2014-01-31End: 2016-01-31Updated: 2022-05-27

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

RecruitingNCT03297606

Canadian Cancer Trials GroupAdvanced Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma

Start: 2018-03-23End: 2027-01-31Target: 720Updated: 2026-03-27

Related Papers

ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial

BMC Cancer2023-02-2223 citations

Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.

Journal of Clinical Oncology2019-05-201 citations

Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.

Journal of Clinical Oncology2019-01-291 citations

Canadian profiling and targeted agent utilization trial (CAPTUR/PM.1): A phase II basket precision medicine trial.

Journal of Clinical Oncology2018-05-2018 citations